Catalyst Biosciences, Inc. (NASDAQ:CBIO) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Monday.
According to Zacks, “Catalyst Biosciences, Inc. is a biopharmaceutical company which focused on creating and developing medicines to address serious medical conditions. The Company’s hemostasis product candidates include CB 813d/PF-0520602, CB 2679d/ISU 304 and FXa. Anti-Complement Product consists of CB 2782 and Ophthalmic which are in clinical different trail. Catalyst Biosciences, Inc., formerly known as Targacept, Inc., is based in South San Francisco, Calif. “
Catalyst Biosciences (NASDAQ:CBIO) traded up 22.90% during midday trading on Monday, hitting $9.50. The stock had a trading volume of 427,626 shares. Catalyst Biosciences has a 1-year low of $0.45 and a 1-year high of $10.95. The stock’s market cap is $114.25 million. The company has a 50-day moving average of $0.61 and a 200-day moving average of $0.93.
This news story was published by sleekmoney and is the sole property of of sleekmoney. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this news story can be viewed at http://sleekmoney.com/catalyst-biosciences-inc-cbio-raised-to-hold-at-zacks-investment-research/1658964.html.
An institutional investor recently raised its position in Catalyst Biosciences stock. Renaissance Technologies LLC increased its stake in Catalyst Biosciences, Inc. (NASDAQ:CBIO) by 105.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 385,450 shares of the biopharmaceutical company’s stock after buying an additional 198,000 shares during the period. Renaissance Technologies LLC owned about 3.21% of Catalyst Biosciences worth $251,000 as of its most recent SEC filing. 33.55% of the stock is currently owned by institutional investors.
Catalyst Biosciences Company Profile
Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/catalyst-biosciences-inc-cbio-raised-to-hold-at-zacks-investment-research/1658964.html
Receive News & Ratings for Catalyst Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.